Daniel Geffken

Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA.

CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA.

Codon Devices, Inc. produces pharmaceuticals and biorefineries for the production of industrial chemicals and bio-energy. The firm designs and constructs biological components such as enzymes, biopharmaceuticals, and cell lines for improved function. Its customers include the biotechnology, pharmaceutical, and agriculture sectors. The company was founded by Noubar B. Afeyan, George Church, Drew Endy, Joseph M. Jacobson and Jay Keasling in 2004 and is headquartered in Cambridge, MA.

Gelesis, Inc. operates as a consumer-centered biotherapeutics company, which engages in the development of novel therapies to induce weight loss and metabolic disorders. Its commercial product portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease /Non-alcoholic Steatohepatitis, and Functional Constipation. The company was founded by Yishai Zohar in 2006 and is headquartered in Boston, MA.

Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA.

Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel.

Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA.

Sideris Pharmaceuticals, Inc. operated as a biopharmaceutical company. It focused on development of therapeutics for the treatment of transfusion related iron overload. The company was founded by Raymond Bergeron and Thomas Neenan on June 1, 2012 and was headquartered in Lexington, MA.

Windgap Medical, Inc. engages in the development of epinephrine autoinjector for the treatment of anaphylaxis. The company was founded was founded by Christopher J. Stepanian and Brent Buchine and is headquartered in Somerville, MA.

Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA.

Cyberkinetics Neurotechnology Systems, Inc. manufactures medical devices. The company was founded by John Donoghue on February 6, 2002 and is headquartered in Foxborough, MA.

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

Seaside Therapeutics LLC engages in the development of drug treatments to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders. Its products include STX209, STX107, and STX110. The company was founded by Randall L. Carpenter and Mark F. Bear in 2005 and is headquartered in Cambridge, MA.

Nemucore Medical Innovations, Inc. is a clinical development company. It specializes in the development and commercialization of molecularly targeted therapeutics for the treatment of multi-drug resistant cancers with an emphasis on women's oncology. The company was founded by Timothy P. Coleman, Yuri Lvov, Vladimir Torchilin and Mansoor Amiji in 2008 and is headquartered in Wellesley, MA.

Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA.

GenePeeks, Inc. develops software that provides genetic information to reduce the risk of heritable diseases. It simulates the genetic reduction and recombination by digitally weaving together the DNA of prospective parents. The company was founded by Anne Morriss and Lee Silver in 2009 and is headquartered in Albany, NY.

Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA.

Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA.

Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA.

Part of Vaxxinity, Inc., United Neuroscience Ltd. is an Irish clinical stage biotech company. The company is based in Dublin, Ireland.

Vyriad, Inc. manufactures pharmaceutical products for cancer. Its technology include pipeline, non-invasive imaging, and oncolytic vaccine development. The company was founded by Stephen J. Russell, Glen Barber, Shruthi Naik, Kah Whye Peng, and Mark Federspiel in 2016 and is headquartered in Rochester, MN.

Antolrx, Inc. operates in the healthcare industry focusing on biotechnology business. The company was founded by Mark Carthy and is headquartered in Boston, MA.

Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA.

Arcturus Therapeutics Ltd. engages in the provision of RNA medicines, which focuses on liver and respiratory diseases. Its RNA medicines include mRNA; siRNA, miRNA, and ASO;, CRISPR, TALEN, and meganucleases; and Replicon RNA and DNA. The company was founded by Joseph Payne in March 2013 and is headquartered in San Diego, CA.

DermBiont, Inc. operates as an early stage biopharmaceutical company that engages in discovery and development of live bacterial products for the treatment of skin diseases. It develops skin microbiome therapeutics platform to treat and prevent skin diseases. The company was founded by Karl R. Beutner, Robert M. Brucker and Nichola Eliovits in 2017 and is headquartered in Boston, MA.

Clear Creek Bio, Inc. engages in the development of therapies that target nucleotide synthesis pathways. The firm focuses on the differentiation blockade in cancer and suppress replication of RNA-based viruses. It uses pharmacodynamic markers to ensure that each patient gets the right drug at the correct dose. The company was founded by David T. Scadden, David B. Sykes, Burt A. Adelman, and Vikram Sheel Kumar in 2017 and is headquartered in Cambridge, MA.

Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in Needham, MA.

Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA.

SG DAN Holdings LLC operates as an investment holding firm. The company is headquartered in New York, NY.

Apic Bio, Inc. engages in the development of treatment for neurological and liver diseases. It offers THRIVE, a platform that silences a mutant gene product and replaces a normal gene product in a single dual function vector. The company was founded by Robert H. Brown, Jr., John Reilly, and Christian Mueller in 2017 and is headquartered in North Cambridge, MA.

Privo Technologies, Inc. engages in biotechnology company. The firm focuses on oral cancer, intra-opertaive chemotherapy and HPV caused cancers. The company was founded by Manijeh Goldberg and is headquartered in Peabody, MA.

Part of Prilenia Therapeutics BV, Prilenia Therapeutics Development Ltd. is a clinical stage biotech company based in Herzliya, Israel. Prilenia Therapeutics is developing its lead drug candidate, pridopidine, which is a sigma-1 receptor agonist and is in clinical development for the treatment of ALS and Huntington's disease. Pridopidine is currently part of the Healey ALS platform phase 2/3 clinical study and is in a phase 3 trial (PROOF-HD) with the Huntington Study Group, addressing functional capacity in early-stage HD patients. The pridopidine pipeline includes further indications in the pre-clinical phase. The Israeli company was founded by Michael R. Hayden in 2018 with the purpose of developing treatments for neurodegenerative and neurodevelopmental disorders.

Myeloid Therapeutics, Inc. operates as an immuno-oncology company that engages in the development of cell program to cure cancer. It offers ATAK platform, a cell therapy technology. The company was founded by Ronald Vale, Siddhartha Mukherjee, Daniel Getts, and Thomas Cahill in 2019 and is headquartered in Cambridge, MA.

Matrivax Research & Development Corp. is developing human vaccines for the prevention and treatment of life-threatening bacterial diseases. Its pipeline includes two vaccine candidates implementing proprietary streptococcus pneumoniae and clostridium difficile protective antigens. The company was founded in October 2007 and is headquartered in Boston, MA.

Locust Walk Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on October 2, 2020 and is headquartered in Boston, MA.

Arcturus Studios Holdings, Inc. specializes in editing and compressing volumetric video through their holostream and holosuite products. Arcturus Studios Holdings is based in Beverly Hills, CA and has subsidiaries in Canada. These products provide adaptive streaming volumetric video for uninterrupted experiences delivered on demand. The company has received positive feedback from clients such as Crescent Studios, Far East Company, Inc., and NTT Docomo, Inc. for their professional-grade tools and ability to anticipate customer needs. Holoedit and holosuite have been used in various projects, including those featuring BTS and the 2019 Samsung Developer Conference. The company was founded by Devin Horsman, Andy Stack, and Ewan Johnson, and the CEO is Kamal Mistry.

Phoenix Biotech Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on June 8, 2021 and is headquartered in Oakland, CA.

OPY Acquisition Corp. I is blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination. The company was founded July 20, 2020 and is headquartered in New York, NY.

Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA.